Granules India Limited
Goldman Sachs bought 11,73,916 shares of Granules India Limited for ₹102.42 Cr at ₹872.50 apiece in a block deal.
A pharmaceutical manufacturer engaged in producing Active Pharma Ingredients, Pharmaceutical Formulation Intermediates, and finished dosages for global markets. Granules India operates integrated manufacturing facilities across multiple locations in India, serving domestic and international customers in the pharmaceutical sector. The company specializes in complex chemical synthesis and formulation development for various therapeutic categories, including antibiotics, cardiovascular, and gastroenterology segments.
US-based global investment bank (USD 1.6 trillion in assets, USD 3 trillion+ in client AUM through Goldman Sachs Asset Management). India FPI activity covers proprietary, market-making, client flows and active asset management mandates in listed Indian equities.